
Julen Cadiñanos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7925605/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virus–Infected Recipients of Long-term Antiretroviral Treatment. Journal of Infectious Diseases, 2022, 225, 287-294.	4.0	10
2	Pacemaker pocket infection by Nocardia carnea. First case description and literature review. Microbes and Infection, 2022, 24, 104944.	1.9	0
3	Ageing with HIV: Challenges and biomarkers. EBioMedicine, 2022, 77, 103896.	6.1	29
4	Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. Journal of Antimicrobial Chemotherapy, 2021, 76, 738-742.	3.0	22
5	Risks and benefits of reducing the number of drugs to treat HIV-1 infection. Expert Opinion on Drug Safety, 2021, 20, 397-409.	2.4	14
6	Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV,the, 2021, 8, e197-e205.	4.7	46
7	Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study). Journal of Antimicrobial Chemotherapy, 2021, 76, 3263-3271.	3.0	5
8	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMedicine, 2020, 55, 102779.	6.1	28
9	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	3.3	41
10	Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clinical Epidemiology, 2014, 6, 369.	3.0	172